Biochemical effects of quipazine on rat striatal dopaminergic system

At high doses quipazine, a serotonergic agonist, induces a dose-dependent reduction of homovanillic acid (HVA) and of dihydroxyphenylacetic acid (DOPAC) levels in rat striatum, and reduces the conversion of tyrosine into dopamine. These effects are not mediated by a serotonergic-dopaminergic interaction as they are not antagonized by pretreatment with the serotonin antagonist methergoline. Neither are they caused by direct action on dopamine receptors as the drug does not antagonize the increase in HVA induced by haloperidol. 3-methoxytyramine (3MT), a DA metabolite which is the expression of DA present in the synaptic cleft, is high after quipazine treatment, but this is not because of monoamine oxidase inhibition. The increase in 3MT is already evident shortly after quipazine administration, while the effect on HVA and DOPAC levels appears later. The different effects of quipazine on DA metabolites and the temporal sequence of their appearance suggest that the lowered levels of acidic metabolites are an index of reduced DA turnover secondary to the increase in DA at the receptor sites caused by quipazine.